Clinical and economic impact of rFVIIa prophylaxis in Glanzmann thrombasthenia: cohort analysis in Saudi Arabia Authors: Ahmad Tarawah, Sami Albattat, Ayman Shahba, Mohamed Nashat, Sarah Brighton, Emily Back, Sam Bristow, George Morgan Published: 2026 ABSTRACT Key Points•rFVIIa prophylaxis was associated with reduced treated bleeds, hospitalization, and platelet transfusion use in severe GT.•Reduced acute care costs partially offset increased rFVIIa costs, resulting in approximate cost neutrality. Introduction Glanzmann thrombasthenia (GT) is an ultrarare inherited platelet disorder characterized by quantitative or qualitative abnormalities in the αIIbβ3 integrin receptor, resulting in impaired platelet aggregation and a lifelong bleeding tendency.1,2 Patients with severe GT phenotypes experience substantial disease burden, including recurrent mucocutaneous bleeding, life-threatening hemorrhages, frequent hospitalizations, and requirement for platelet transfusion.3,4 In females, heavy menstrual bleeding often occurs, with iron deficiency anemia as a common comorbidity because of chronic blood loss, and research shows that this may amplify the occurrence of additional comorbidities, the overall clinical burden, and impairment of quality of life.4, 5, 6, 7 Management of GT has traditionally focused on reactive treatment rather than a preventive approach, with on-demand treatment of acute bleeding episodes using antifibrinolytics, platelet or blood transfusions, or recombinant activated factor VII (rFVIIa).4,8,9 Although rFVIIa has demonstrated efficacy in both acute and prophylactic treatment, prophylactic use has not become routine standard care, and published evidence remains limited.10, 11, 12, 13, 14, 15 In Saudi Arabia and other Gulf Cooperation Council countries, rFVIIa is recommended as first-line therapy for GT in the 2019 regional consensus guideline; however, prophylaxis has generally been reserved for patients with severe recurrent bleeding. In addition to the need for frequent IV administration, uncertainty regarding long-term feasibility and concerns surrounding economic sustainability have further limited the evidence base for prophylactic treatment. Critical gaps persist in understanding the real-world impact of GT prophylaxis. Although case series have reported reduced bleeding frequency with prophylactic rFVIIa, comprehensive analyses quantifying health care resource use and direct medical costs are lacking.14, 15, 16 The economic implications of prophylaxis are particularly salient, given the high acquisition costs of rFVIIa and the need for frequent administration because of its short half-life of 2 to 3 hours.17, 18, 19 Without evidence demonstrating that clinical benefits translate into manageable or offset costs, health care systems and payers have limited basis to support widespread prophylaxis implementation.14,15 This study aimed to characterize clinical outcomes and direct medical costs in a cohort of pediatric patients with severe GT receiving rFVIIa prophylaxis at a specialized tertiary center in Saudi Arabia. Using intrapatient comparisons between prophylaxis and preprophylaxis periods, we evaluated bleeding outcomes, hospitalization burden, platelet use, and direct medical costs to estimate the clinical and economic impact of prophylactic treatment. Methods Study design and setting We conducted a prospective clinical study evaluating rFVIIa prophylaxis in pediatric patients with GT at the Hereditary Blood Disorders Center, King Salman Medical City, Madinah, Saudi Arabia, which manages >100 patients with GT. The analysis compared clinical outcomes and health care costs between a prophylaxis period and a historical control period of equal duration for each patient, providing intrapatient controls to minimize confounding from phenotypic heterogeneity. Patient population Children aged between 2 and 14 years with confirmed GT were eligible if they met the predefined criteria for a severe bleeding phenotype, defined as either ≥2 bleeding episodes every 3 months (≥6 episodes annually) or ≥3 major bleeding events requiring hospitalization and treatment with rFVIIa or platelet transfusion annually. The sample included all eligible patients within the center who received prophylactic rFVIIa and for whom complete resource use data were available. Informed consent was obtained for all patients before they took part in the study; ethics approval was provided by the institutional review board of the Maternity and Children Hospital, Madinah, Saudi Arabia. Patients with any missing data were not included. The final cohort comprised 11 patients. Prophylaxis regimen and data collection Study participants received prophylactic rFVIIa at a dose of 270 μg/kg administered either every other day or 3 times weekly, delivered via peripheral venous access or Port-a-Cath, based on individual vascular access considerations. The prophylactic dose was selected according to local clinical practice at the study center based on the standard rFVIIa dosing regimen used in Saudi Arabia for patients with hemophilia and inhibitors. Prophylaxis could be temporarily halted if patients experienced no bleeding episodes for 3 consecutive months, resuming upon rebleeding. The observation period concluded upon the patient reaching 14 years of age or after 6 consecutive months without bleeding. Data for the prophylaxis period were sourced from data collected during the clinical study in early 2019. Historical control data spanning an equivalent duration before prophylaxis initiation were extracted from medical records. Data collected for both periods included rFVIIa consumption (micrograms), number of treated bleeding episodes, total hospital days, and platelet transfusion units. In addition, sex assigned at birth, prophylaxis access method, duration of the prophylaxis period (including months in which prophylaxis was halted), and age at the start and end of the prophylaxis period were collected. During the study, patients were not permitted to administer rFVIIa at home and were required to report bleeding episodes to King Salman Medical City for clinical assessment and treatment. Consequently, the analysis included treated bleeding episodes recorded within the treating center, with untreated bleeds outside the health care setting not captured. Unit costs Direct medical costs were calculated by applying unit costs sourced from Saudi Arabia, or an appropriate representative country when this was not feasible, to resource use quantities. Unit costs were derived from published literature and were expressed in 2025 Saudi riyals (SAR). Full details of unit costing assumptions are available in supplemental Table 1. The unit costs sourced were 4171.49 SAR per microgram for rFVIIa, 1309.42 SAR per day for hospitalization, and 4478 SAR per unit for platelets.20, 21, 22 Costs were calculated for the prophylaxis and historical control periods for each cost component (rFVIIa, hospitalization, and platelet transfusions) according to equation 1 (component cost calculation):componentcost=quantity×unitcost Total costs for each period were computed as the sum of all component costs. All values were annualized to account for varying observation periods using equation 2 (annualization):annualizedvalue=(totalforperiodperioddurationinmonths)×12 Clinical and economic impact measures The clinical impact measures calculated were the difference in (1) treated bleed frequency, (2) hospitalization burden (days in hospital), and (3) platelet use. These measures calculated the difference between the prophylaxis and control period for each clinical area of interest. We also present 4 key economic metrics: incremental rFVIIa cost, incremental hospital cost, incremental platelet transfusion cost, and net annual cost impact. The incremental costs are the difference in costs between the prophylaxis and control periods for the relevant component. Net annual cost impact, the overall difference in cost between the prophylaxis and control periods, is the sum of the 3 incremental costs calculated. Differences were calculated at the individual patient level, with annualized values used throughout. Statistical analysis Given the small sample size and skewed data distributions, results are summarized using medians and interquartile ranges (Q1-Q3) to be less sensitive to outliers and more representative of the typical patient experience. Given the small sample size, nonnormal data distribution, and paired nature of the between-period comparison, the Wilcoxon signed-rank test was used alongside effect size (r) to compare distributions. Statistical significance was assessed as P < .05. When within-patient differences are presented for the clinical and economic impact measures, results are summarized using the median of the individual differences. A 95% confidence interval was also estimated for these measures. All analyses were conducted at the patient level. Results stratified by sex (assigned at birth) were also calculated. A deterministic sensitivity analysis was conducted by varying each unit cost (rFVIIa, hospitalization, and platelet transfusion costs) by ±20% individually and in combination to assess the robustness of the economic findings to plausible variation in costing assumptions. Statement on studies in humans and animals Ethics approval for this study was obtained from the institutional review board of the Maternity and Children Hospital, Madinah, Saudi Arabia. All procedures conformed to the Declaration of Helsinki. Written informed consent was obtained from all participants or their parent/guardian. Results Demographics The total sample comprised 11 patients, of whom 7 (64%) were male, and 4 (36%) were female. Median age at the start of the study (at the commencement of prophylaxis) was 6 years. Median duration of the prophylaxis period was 18 months. The demographic characteristics of the sample are presented in Table 1.Table 1.Demographic characteristicsMedian (Q1-Q3)Total sample (N = 11)Male (n = 7)Female (n = 4)Age at start of study, y6.00 (5.00-7.00)7.00 (5.00-8.00)5.50 (4.50-6.00)Age at end of study, y7.75 (4.00-9.00)7.75 (4.00-12.00)6.88 (4.38-9.00)Duration of prophylaxis, mo18.00 (9.00-37.00)18.00 (9.00-42.00)24.50 (10.50-37.00)Weight during study, kg19.00 (15.00-30.00)17.50 (14.00-30.00)26.00 (20.50-32.00) Table 1.Demographic characteristicsMedian (Q1-Q3)Total sample (N = 11)Male (n = 7)Female (n = 4)Age at start of study, y6.00 (5.00-7.00)7.00 (5.00-8.00)5.50 (4.50-6.00)Age at end of study, y7.75 (4.00-9.00)7.75 (4.00-12.00)6.88 (4.38-9.00)Duration of prophylaxis, mo18.00 (9.00-37.00)18.00 (9.00-42.00)24.50 (10.50-37.00)Weight during study, kg19.00 (15.00-30.00)17.50 (14.00-30.00)26.00 (20.50-32.00) Demographic characteristics Clinical outcomes All 11 patients demonstrated reduced treated bleeding episodes during prophylaxis compared with the control period. Median annualized bleeding frequency decreased from 10 events per year during the control period to 4 events per year in the prophylaxis period, representing a 60% reduction in the median (P = .001). This improvement was consistent across sex-stratified analyses: males experienced a reduction in median treated bleeds from 10 to 4 bleeds annually, whereas median treated bleeds in females decreased from 9.5 to 4 bleeds annually. Median annualized hospital days decreased from 96 days in the control period to 24 days during prophylaxis, representing a 75% reduction. Male patients averaged 78 hospital days in the control period annually vs 15 days on prophylaxis. For female patients, median hospital days decreased from 103.5 to 29 annually. The reduction in hospitalization burden was statistically significant (P = .001 for the total sample). Median annualized platelet consumption fell from 63 units during the control period to 6 units during prophylaxis, representing a 90% reduction in median platelet use (P = .001). This decline was evident in both male (from 57 to 5 units) and female (from 70 to 6 units) cohorts. Effect sizes for all 3 metrics showed strong effects (r < −0.75). Full descriptive results are included in supplemental Table 2. Despite substantial clinical improvements, response heterogeneity was evident. Patient GTN7PRO-9 demonstrated minimal benefit from prophylaxis, with bleeding episodes decreasing only from 12 to 10 and hospital days decreasing from 89 to 85 annually, and had the highest annualized quantity of rFVIIa consumption in both periods. The clinical complexity of this patient, including angiodysplasia confirmed by endoscopy with dye-enhanced imaging during the prophylaxis period, should be acknowledged. Notably, 7 of the 11 patients required higher annualized rFVIIa consumption during the prophylaxis period than during the control period, reflecting the regular dosing required for preventive vs episodic use. However, across the entire sample, the difference in annualized rFVIIa consumption between the 2 periods was not statistically significant (P = .3105). Economic outcomes Median annualized rFVIIa costs were 1 451 679 SAR during prophylaxis vs 1 968 943 SAR during the control period in the total sample, with a moderate effect size, although this difference did not reach statistical significance (P = .3105; r = 0.3219). However, significant reductions occurred in annualized hospitalization costs (31 426 SAR prophylaxis vs 125 704 SAR control; P = .0156) and platelet transfusion costs (26 868 SAR prophylaxis vs 282 114 SAR control; P = .0156), with a strong effect observed (r < −0.75). Total median annualized costs were 1 492 401 SAR during prophylaxis, compared with 2 427 749 SAR during the control period, representing a decrease in median cost of 935 348 SAR. However, this difference did not achieve statistical significance (P = .8135) and had only a weak effect (r = 0.0805). Heterogeneity of costs was evident, for instance, in patient GTN7PRO-9, whose annual costs increased markedly during prophylaxis (5 520 189 SAR control vs 11 500 000 SAR prophylaxis). Sex-stratified analyses revealed important differences. Male patients demonstrated median annualized total costs of 938 016 SAR during prophylaxis vs 2 178 270 SAR during the control period, whereas female patients showed median annualized costs of 2 784 653 SAR during prophylaxis vs 2 427 749 SAR during the control period. Full results are included in supplemental Table 3. Clinical impact analysis All clinical impact measures demonstrated a reduction in clinical burden in the prophylaxis compared with the control period, consistent throughout sex-stratified analyses (Table 2). The median intrapatient difference in annualized treated bleed frequency across the sample was −4, meaning a median of <4 bleeds were experienced annually in each patient in the prophylaxis compared with the control period. The median intrapatient decrease in hospital days was 82, and the median intrapatient decrease in platelet consumption was 53 units. Although heterogeneity was evident in the degree of clinical impact, all patients experienced a reduction in clinical burden across all measures (Figure 1).Table 2.Clinical impact measuresMedianQ1-Q395% CITotal (N = 11) Difference in annualized treated bleed frequency, bleeds/y−4.00−8.00 to −3.00−8.00 to −2.00 Difference in annualized hospitalization burden, d/y−82.00−87.00 to −48.00−99.00 to −4.00 Difference in annualized platelet use, units/y−53.00−64.00 to −41.00−247.00 to −6.00Male (n = 7) Difference in annualized treated bleed frequency, bleeds/y−5.00−8.00 to −3.00−8.00 to −2.00 Difference in annualized hospitalization burden, d/y−60.00−91.00 to −48.00−99.00 to −36.00 Difference in annualized platelet use, units/y−51.00−54.00 to −41.00−247.00 to −32.00Female (n = 4) Difference in annualized treated bleed frequency, bleeds/y−3.00−5.50 to −2.50−8.00 to −2.00 Difference in annualized hospitalization burden, d/y−82.00−84.50 to −43.00−87.00 to −4.00 Difference in annualized platelet use, units/y−63.50−64.00 to −34.50−64.00 to −6.00CI, confidence interval.Figure 1.Per-patient clinical impact of prophylaxis. The figure shows the percentage reduction in the number of bleeds, days in hospital, and units of platelets used in the prophylaxis compared with the preprophylaxis period at an individual patient level. Table 2.Clinical impact measuresMedianQ1-Q395% CITotal (N = 11) Difference in annualized treated bleed frequency, bleeds/y−4.00−8.00 to −3.00−8.00 to −2.00 Difference in annualized hospitalization burden, d/y−82.00−87.00 to −48.00−99.00 to −4.00 Difference in annualized platelet use, units/y−53.00−64.00 to −41.00−247.00 to −6.00Male (n = 7) Difference in annualized treated bleed frequency, bleeds/y−5.00−8.00 to −3.00−8.00 to −2.00 Difference in annualized hospitalization burden, d/y−60.00−91.00 to −48.00−99.00 to −36.00 Difference in annualized platelet use, units/y−51.00−54.00 to −41.00−247.00 to −32.00Female (n = 4) Difference in annualized treated bleed frequency, bleeds/y−3.00−5.50 to −2.50−8.00 to −2.00 Difference in annualized hospitalization burden, d/y−82.00−84.50 to −43.00−87.00 to −4.00 Difference in annualized platelet use, units/y−63.50−64.00 to −34.50−64.00 to −6.00CI, confidence interval. Clinical impact measures CI, confidence interval. Per-patient clinical impact of prophylaxis. The figure shows the percentage reduction in the number of bleeds, days in hospital, and units of platelets used in the prophylaxis compared with the preprophylaxis period at an individual patient level. Economic impact analysis The median intrapatient incremental rFVIIa cost for prophylaxis was 229 432 SAR annually. However, this was offset by savings from reduced clinical burden, translating to a median intrapatient incremental hospital cost of −107 372 SAR and median intrapatient incremental platelet transfusion cost of −237 334 SAR annually. Consequently, the median net annual cost impact was −1305 SAR. Male patients demonstrated greater cost efficiency in the prophylaxis period, with a median net annual cost impact of −681 698 SAR, compared with female patients, who showed a median net cost increase of 361 075 SAR (full sex-stratified results are presented in Table 3).Table 3.Economic impact measures (SAR)MedianQ1-Q395% CITotal (N = 11) Net annual cost impact, SAR/y−1 305−1 344 157 to 1 679 956−3 224 841 to 5 949 812 Incremental rFVIIa cost, SAR/y229 432−475 550 to 2 035 687−2 949 244 to 5 981 917 Incremental hospital cost, SAR/y−107 372−113 920 to −62 852−129 633 to −5 238 Incremental platelet transfusion cost, SAR/y−237 334−286 592 to −183 598−1 106 066 to −26 868Male (n = 7) Net annual cost impact, SAR/y−681 698−1 501 089 to 1 679 956−3 224 841 to 3 444 349 Incremental rFVIIa cost, SAR/y−108 459−1 193 046 to 2 035 687−2 949 244 to 3 791 885 Incremental hospital cost, SAR/y−78 565−119 157 to −62 852−129 633 to −47 139 Incremental platelet transfusion cost, SAR/y−228 378−241 812 to −183 598−1 106 066 to −143 296Female (n = 4) Net annual cost impact, SAR/y361 07574 294 to 3 155 443−212 488 to 5 949 812 Incremental rFVIIa cost, SAR/y755 040469 293 to 3 368 478183 546 to 5 981 917 Incremental hospital cost, SAR/y−107 372−110 646 to −56 305−113 920 to −5 238 Incremental platelet transfusion cost, SAR/y−284 353−286 592 to −154 491−286 592 to −26 868CI, confidence interval. Table 3.Economic impact measures (SAR)MedianQ1-Q395% CITotal (N = 11) Net annual cost impact, SAR/y−1 305−1 344 157 to 1 679 956−3 224 841 to 5 949 812 Incremental rFVIIa cost, SAR/y229 432−475 550 to 2 035 687−2 949 244 to 5 981 917 Incremental hospital cost, SAR/y−107 372−113 920 to −62 852−129 633 to −5 238 Incremental platelet transfusion cost, SAR/y−237 334−286 592 to −183 598−1 106 066 to −26 868Male (n = 7) Net annual cost impact, SAR/y−681 698−1 501 089 to 1 679 956−3 224 841 to 3 444 349 Incremental rFVIIa cost, SAR/y−108 459−1 193 046 to 2 035 687−2 949 244 to 3 791 885 Incremental hospital cost, SAR/y−78 565−119 157 to −62 852−129 633 to −47 139 Incremental platelet transfusion cost, SAR/y−228 378−241 812 to −183 598−1 106 066 to −143 296Female (n = 4) Net annual cost impact, SAR/y361 07574 294 to 3 155 443−212 488 to 5 949 812 Incremental rFVIIa cost, SAR/y755 040469 293 to 3 368 478183 546 to 5 981 917 Incremental hospital cost, SAR/y−107 372−110 646 to −56 305−113 920 to −5 238 Incremental platelet transfusion cost, SAR/y−284 353−286 592 to −154 491−286 592 to −26 868CI, confidence interval. Economic impact measures (SAR) CI, confidence interval. Net cost impact varied considerably between patients, with patient GTN7PRO-11 showing the greatest annual cost decrease and patient GTB7PRO-9 showing the greatest annual cost increase for the prophylaxis compared with the control period (Figure 2).Figure 2.Per-patient cost impact of prophylaxis. The figure shows the incremental rFVIIa cost, incremental hospital cost, incremental platelet transfusion cost, and overall net cost impact of prophylaxis compared with preprophylaxis care at an individual patient level. Per-patient cost impact of prophylaxis. The figure shows the incremental rFVIIa cost, incremental hospital cost, incremental platelet transfusion cost, and overall net cost impact of prophylaxis compared with preprophylaxis care at an individual patient level. Cost sensitivity analysis Deterministic sensitivity analyses demonstrated that the findings were robust to plausible variation in costing assumptions (supplemental Table 4). Across all scenarios, the median net annual cost impact ranged from a saving of 93 339 SAR in the optimistic scenario to an increase of 90 729 SAR in the conservative scenario. Variation in rFVIIa acquisition costs had the greatest influence on results, whereas changes in hospitalization and platelet transfusion costs had a comparatively smaller impact. Discussion This prospective cohort analysis found that rFVIIa prophylaxis in severe GT was associated with reductions in treated bleeding episodes, hospitalization burden, and platelet transfusion requirements compared with the preprophylaxis period. Although rFVIIa acquisition costs increased during prophylaxis, these were partially offset by lower hospitalization and platelet transfusion costs, resulting in the potential for relative cost neutrality, with a median net annual cost impact of −1305 SAR. Clinical implications rFVIIa prophylaxis was associated with reductions in treated bleeding episodes, hospitalization burden, and platelet transfusion requirements compared with the preprophylaxis period. These reductions were statistically significant across all 3 key metrics (treated bleeds, days in hospital, and platelet transfusions required). Findings were consistent with previous evidence supporting prophylactic approaches in severe bleeding disorders.23 However, the regimen used in this study required frequent IV administration (every other day or 3 times weekly), which has been shown to present challenges for treatment adherence and long-term feasibility in other bleeding disorders.23, 24, 25 Although safety outcomes were not formally evaluated, no clinically recognized treatment- or vascular access–related complications attributable to prophylactic rFVIIa were observed during the study period, including thrombophlebitis, thrombosis, central venous access device occlusion, or line-related fever/infection. Nevertheless, longer-term evaluation of adherence, safety, and treatment burden remains warranted. Future treatments have the potential to address this issue because the introduction of longer-acting products can overcome such barriers through less frequent dosing.23 In addition, reduced platelet use may also have important clinical implications by limiting platelet exposure and reducing the risk of alloimmunization and future platelet refractoriness.26 The heterogeneity of response to rFVIIa treatment, illustrated through the experience of patient GTB7PRO-9, highlights the need for personalized care in patients with GT. In this case, the patient developed angiodysplasia during the prophylaxis period. Although withdrawal from the study was considered, the patient remained eligible because the inclusion criteria did not specify bleed type. This underscores the clinical complexity of GT and the challenges of capturing the full spectrum of bleeding presentations within standardized study frameworks. Previous research has noted the importance of management plans for patients with GT tailored to the individual, considering location and severity of bleeding, availability of treatments, and antibody status, with particular provision for menstrual bleeding and perioperative care, consistent with findings in hemophilia care, whereas heterogeneity of bleeding profile is a key feature.8,23,27 Economic implications The key finding of a median net cost impact of −1305 SAR suggests the potential for relative cost neutrality when transitioning from on-demand to prophylactic rFVIIa treatment in this population. Deterministic sensitivity analyses demonstrated that this finding was robust to plausible variation in key cost inputs, with net annual cost impact ranging from a saving of 93 339 SAR to an increase of 90 729 SAR across all scenarios evaluated. Although rFVIIa acquisition costs increased during prophylaxis because of regular dosing requirements, these were balanced by lower hospitalization and platelet transfusion costs. Estimates for GT in Saudi Arabia suggest a prevalence of ∼1:200 000.27 Set against a national population of ∼35 million, the median net annual cost impact observed in this study would translate to an estimated overall impact of −228 375 SAR if similar outcomes were observed more broadly.28 However, these findings should be interpreted cautiously, given the small cohort size, single-center design, and heterogeneity of response observed. Differences in cost impact were observed between the male and female cohorts. Male patients demonstrated a median net cost saving (−682 000 SAR), whereas female patients showed a median net cost increase (+361 000 SAR). However, these findings should be interpreted cautiously, given the small cohort size and predominantly premenarcheal pediatric population, which may underestimate the long-term impact of prophylaxis in women with GT who experience cyclical bleeding burden and associated comorbidities. Bleeding burden and treatment requirements are known to vary substantially across patients with GT, particularly in females, for whom heavy menstrual bleeding and iron deficiency anemia may contribute additional long-term burden.6,7,29, 30, 31 Nevertheless, although individual patient profiles may have an impact on the cost-effectiveness of prophylaxis, these findings suggest the potential for relative economic sustainability at a population level. Study context and limitations To our knowledge, this is the first study to estimate the cost impact of prophylaxis in patients with GT. Because this analysis used a small patient cohort (N = 11), further research with a larger sample would help validate the results found in this cohort. However, the single-center approach used by this research, although necessitating a small patient cohort, enables intrapatient comparison, which accounts for confounding from differing bleeding phenotypes that may be present in larger registry-based studies. Furthermore, results use median values to minimize the impact of outliers on the findings and better represent the typical patient experience. The cohort evaluated in this study was managed within a specialist hereditary bleeding disorder center, facilitating high levels of clinical oversight and access to treatment that may not be reproducible across all care settings. Previous work has highlighted challenges in access to care and effective treatment in GT, emphasizing the importance of specialist management in supporting patient outcomes.29,30 Furthermore, this study focused on a pediatric population in Saudi Arabia, and findings may not be directly generalizable to adult populations or health care systems in which treatment practices, access pathways, and costs may differ. The economic analysis focused on direct medical costs and did not capture the wider humanistic or societal burden, including caregiver burden, school attendance, productivity, daily functioning, or quality-of-life impacts. Although reductions in bleeding frequency are likely to improve these outcomes, no patient-reported outcomes (PROs) were collected as part of this study.4,29 Furthermore, no validated GT-specific PRO instrument currently exists, representing both a limitation in the current evidence base and an important area for future research.14 Previous research in bleeding disorders has demonstrated that improved bleed control is associated with improved quality of life and reduced societal burden.32, 33, 34 In addition, unit costs were derived from published sources and may vary across institutions and health care systems. However, deterministic sensitivity analyses demonstrated that the overall conclusions were robust to plausible variation in key costing assumptions. The wider clinical impact of prophylaxis should also be considered. Previous research has identified underreporting and normalization of bleeding symptoms within GT populations.27 Because this analysis captured treated bleeding episodes only, bleeds managed outside health care settings were not included, and the full clinical impact of prophylaxis may therefore be underestimated. It must also be noted that the use of a historical comparator period may introduce ascertainment bias because of differences in the completeness of prospective and retrospective data collection. In addition, although this study focused primarily on acute health care use, improved bleeding control may also reduce longer-term complications associated with chronic blood loss, including iron deficiency–related burden and bleeding-associated comorbidities.6,7,23,29,35 Conclusions rFVIIa prophylaxis was associated with reduced treated bleeding episodes and health care resource use in severe GT. Despite increased rFVIIa acquisition costs, reductions in hospitalization and platelet transfusion costs resulted in the potential for relative cost neutrality in this cohort. Overall, these findings support further evaluation of prophylactic treatment strategies in GT and highlight important unmet needs, including treatment burden, response heterogeneity, long-term feasibility, and the need for PRO data. Conflict-of-interest disclosure: The authors declare no competing financial interests.